| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10746942 | IVR | 0.01 mg/kg | 0.01 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:11914775 | IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Alterations in splenocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Atrophy in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Atrophy of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Prostate atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Atrophy in seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Alterations in splenocytes population | Immunological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Hyperplasia in adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Prostate atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Atrophy of seminal vesicles | Reproductive endocrine-m | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Atrophy of mammary gland | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Ovarian atrophy | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased testis weights | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased weights of seminal vesicles | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased prostate weights | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Abnormal estrous cycles | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased ovarian weights | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased liver weights | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased brain weights | ||
| IVR | 0.2 mg/kg | 0.2 mg/kg | Changes in liver morphology | ||
| PMID:12052007 | IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| PMID:12963004 | IVR | 0.005 - 1.25 mg/kg/day | 0.005 - 1.25 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 - 1.25 mg/kg/day | 0.005 - 1.25 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 - 1.25 mg/kg/day | 0.005 - 1.25 mg/kg/day | Oxidative stress in uterus | Reproductive endocrine-mediated perturbations | |
| PMID:15016594 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects testis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:15162385 | IVR | 0.002 M | 0.002 M | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| PMID:15597897 | IVTH | 0.000000008 M | 0.000000008 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:15866537 | IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg | - | No significant effects observed | - | |
| IVR | 0.00003 mg/kg | - | No significant effects observed | - | |
| IVR | 0.01 mg/kg | - | No significant effects observed | - | |
| IVR | 0.003 mg/kg | - | No significant effects observed | - | |
| IVR | 0.001 mg/kg | - | No significant effects observed | - | |
| IVR | 0.0003 mg/kg | 0.0003 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0003 mg/kg | 0.0003 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| PMID:17157476 | IVR | 0.0004 mg/kg | 0.0004 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.0004 mg/kg | 0.0004 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0004 mg/kg | 0.0004 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:17456458 | IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Affects development of reproductive system | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.000004 mg/kg/day | - | No significant effects observed | - | |
| PMID:17574608 | IVR | 0.05 mg/kg | 0.05 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:17822730 | IVTH | 0.001 mg/L | 0.001 mg/L | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.001 mg/L | 0.001 mg/L | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:17983274 | IVTH | 0.0000000000001 - 0.0000000001 M | 0.0000000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:18096570 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased weights of penis | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Changes in morphology of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Decreased weights of bulbocavernosus muscles/LABC | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0005 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.00005 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.00015 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.0015 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.015 mg/kg/day | 0.015 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.015 mg/kg/day | 0.015 mg/kg/day | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.015 mg/kg/day | 0.015 mg/kg/day | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| PMID:18635664 | IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Altered lordosis | Developmental endocrine-mediated perturbations | |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.000004 mg/kg/day | 0.000004 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:19159674 | IVR | 0.05 mg/L | 0.05 mg/L | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Abnormal estrous cycles in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | - | No significant effects observed | - | |
| IVR | 0.002 mg/L | - | No significant effects observed | - | |
| PMID:19383540 | IVR | 2 mg/L | 2 mg/L | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Hyperplasia in mammary glands | Reproductive endocrine-mediated perturbations | |
| PMID:21314741 | IVR | 0.01 mg/kg | 0.01 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg | 0.01 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| PMID:22428746 | IVR | 0.05 mg/kg | 0.05 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.015 mg/kg | 0.015 mg/kg | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.015 mg/kg | 0.015 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:22488762 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| PMID:23160314 | IVR | 0.001 mg/L | 0.001 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations |
| IVR | 0.001 mg/L | 0.001 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.001 mg/L | 0.001 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/L | 0.001 mg/L | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/L | 0.0001 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/L | 0.0001 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.0001 mg/L | 0.0001 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | 0.01 mg/L | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/L | 0.01 mg/L | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:23660487 | IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Delayed puberty | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | - | No significant effects observed | - | |
| IVR | 0.015 mg/kg/day | - | No significant effects observed | - | |
| PMID:24036065 | IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in number of nipples | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg | 0.005 mg/kg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 0.015 mg/kg | 0.015 mg/kg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| PMID:24632129 | IVR | 2 mg/kg | 2 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| PMID:24752507 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:24916741 | IVR | 0.1 mg/kg | 0.1 mg/kg | Affects fatty acid metabolism | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| PMID:25615539 | IVR | 0.02 mg/kg | 0.02 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.02 mg/kg | 0.02 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00002 mg/kg | 0.00002 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg | 0.0002 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.0002 mg/kg | 0.0002 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| PMID:25615633 | IVR | 0.00000025 mg | 0.00000025 mg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 0.00000025 mg | 0.00000025 mg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:26640081 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0001 mg/kg/day | 0.0001 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:26696819 | IVR | 0.001 mg/kg | 0.001 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.001 mg/kg | 0.001 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 0.0001 mg/kg | 0.0001 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:26852889 | IVR | 0.015 mg/kg/day | 0.015 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| IVR | 0.015 mg/kg/day | 0.015 mg/kg/day | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:27512153 | IVR | 0.2 mg/kg | 0.2 mg/kg | Induce apoptosis of ovarian follicles | Reproductive endocrine-mediated perturbations |
| PMID:27917613 | IVR | 0.01 mg/kg | 0.01 mg/kg | Increased prostate weights | Reproductive endocrine-mediated perturbations |
| PMID:28196854 | IVR | 0.0001 mg/L | 0.0001 mg/L | Affects social behavior | Neurological endocrine-mediated perturbations |
| PMID:28522409 | IVR | 0.2 mg/kg | 0.2 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:28736173 | IVR | 0.001 mg/kg/day | 0.001 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:29107581 | IVR | 0.001 mg/kg/day | - | No significant effects observed | - |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/kg/day | 0.00001 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:29112739 | IVR | 0.0025 mg/kg | - | No significant effects observed | - |
| PMID:29649501 | IVR | 20 mg/kg | 20 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:29935216 | IVR | 0.1 mg/kg | 0.1 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects calcium signaling | Metabolic endocrine-mediated perturbations | |
| PMID:30001178 | IVR | 0.0005 mg/kg/day | 0.0005 mg/kg/day | Affects sexual behavior in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:30315872 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:31463084 | IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.0004 mg/kg/day | 0.0004 mg/kg/day | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00004 mg/kg/day | 0.00004 mg/kg/day | Affects prostate development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.